HAE241220P40000
- 0.00
- 0.000.00%
Haemonetics Newsroom
Express News | Needham Reiterates Buy on Haemonetics, Maintains $112 Price Target
Haemonetics to Sell Whole Blood Assets to GVS for $67.1 Million
Haemonetics: To Use Proceeds for General Corporate Purposes and Growth Initiatives>HAE
Haemonetics: Transaction Expected to Close in First Quarter of 2025 >HAE
Express News | Haemonetics Corp - Deal Valued at up to $67.1 Million
Express News | Haemonetics Announces Sale of Whole Blood Assets to Gvs, S.p.a
Press Release: Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A
ABT Stock Benefits From First Patient Procedures With TAVI System
Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), Alcon (ALC)
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
International Expansion Supports BSX Stock Amid Macroeconomic Woes
Haemonetics Corporation's (NYSE:HAE) P/E Is On The Mark
Express News | Haemonetics Q2 Adjusted Free Cash Flow USD 49 Million
Express News | Haemonetics Q2 EPS USD 0.66
Express News | Haemonetics Q2 Adjusted EPS USD 1.12 Vs. IBES Estimate USD 1.07
Express News | Haemonetics Q2 Revenue USD 346 Million Vs. IBES Estimate USD 342.6 Million
Here's Why You Should Add OMCL Stock to Your Portfolio Now
Needham Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $112
Strategic Investment and Growth Potential Drive Buy Rating for Haemonetics
Haemonetics Management to Meet Virtually With BTIG